炔雌醇-屈螺酮混合物 | 164017-31-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 炔雌醇-屈螺酮混合物
• 中文别名: 屈螺酮+炔雌醇,复方
• 英文名称: Gianvi
• 英文别名: (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione;(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 164017-31-6
• 化学式: C44H54O5
• 分子量: 662.9
• InChiKey: JLQFVGYYVXALAG-CFEVTAHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.92
• 重原子数：
  49
• 可旋转键数：
  1
• 环数：
  11.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• USE OF FERRIC CITRATE IN PREVENTION AND/OR TREATMENT OF IRON-DEFICIENCY ANEMIA IN HYPERMENORRHEA PATIENT AND/OR PATIENT SUFFERING FROM HYPERMENORRHEA-ASSOCIATED GYNECOLOGIC DISEASE
  申请人：Japan Tobacco Inc.

  公开号：EP3685831A1

  公开（公告）日：2020-07-29

  The present invention relates to an agent for preventing and/or treating iron-deficiency anemia in patients with hypermenorrhea and/or patients with hypermenorrhea-associated gynecologic diseases. According to the present invention, an agent containing ferric citrate as an active ingredient for preventing and/or treating iron-deficiency anemia in patients with hypermenorrhea and/or patients with hypermenorrhea-associated gynecologic diseases can be provided.

  本发明涉及一种用于预防和/或治疗高月经患者和/或高月经相关妇科疾病患者缺铁性贫血的制剂。根据本发明，可以提供一种含有柠檬酸铁作为活性成分的制剂，用于预防和/或治疗高月经患者和/或高月经相关妇科疾病患者的缺铁性贫血。
• MONOPHASIC CONTRACEPTIVE METHOD AND KIT COMPRISING A COMBINATION OF A PROGESTIN AND ESTROGEN
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0956024A1

  公开（公告）日：1999-11-17
• COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS
  申请人：Charles R Drew University of Medicine and Science

  公开号：EP2875359A2

  公开（公告）日：2015-05-27
• [EN] MONOPHASIC CONTRACEPTIVE METHOD AND KIT COMPRISING A COMBINATION OF A PROGESTIN AND ESTROGEN<br/>[FR] METHODE DE CONTRACEPTION MONOPHASIQUE ET KIT COMPRENANT UNE ASSOCIATION DE PROGESTINE ET D'OESTROGENE
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：WO1998004269A1

  公开（公告）日：1998-02-05

  (EN) This invention provides a method of contraception which comprises administering to a female of child bearing age for a combination of a progestin at a daily dosage of 40-500 μg trimegestone, 250 μg - 4 mg dienogest, or 250 μg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μg ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle, and wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days.(FR) Méthode de contraception consistant à administrer à une femme en âge de procréer une association d'une progestine, selon une posologie quotidienne de 40-500 $g(m)g de trimégestone, 250 $g(m)g-4 mg de diénogest, ou 250 $g(m)g-4 mg de drospirénone, et d'un oestrogène selon une posologie quotidienne équivalant en activité oestrogène à 10-20 $g(m)g d'éthinyloestradiol, pendant 23-25 jours à partir du premier jour du cycle menstruel, la même posologie de l'association de progestine et d'oestrogène étant utilisée chaque jour pendant les 23-25 jours.
• [EN] COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION DE TROUBLES DU SYNDROME MÉTABOLIQUE
  申请人：CHARLES DREW UNIVERSITY OF MEDICINE AND SCIENCE

  公开号：WO2013149258A2

  公开（公告）日：2013-10-03

  The invention provides methods, compositions, uses of compositions, assays and kits for modulating brown adipose tissue (BAT) in animals and patients with obesity, insulin resistance and perturbed glucose homeostasis are disclosed. Accordingly, methods, compositions, uses of compositions, and kits are useful for the amelioration of pathological conditions characterized by storage of excess energy, insulin resistance and related metabolic syndromes often associated with obesity.